Bicara Therapeutics (BCAX)

Executive Summary

Bicara Therapeutics is a clinical-stage biotechnology company pioneering bifunctional biologics that combine tumor-targeting antibodies with immune microenvironment modulators. Its lead asset, ficerafusp alfa, is a novel bispecific molecule that simultaneously blocks EGFR and activates the CD137 costimulatory pathway, designed to enhance anti-tumor immunity while direct attacking cancer cells. The company is currently evaluating ficerafusp alfa in combination with pembrolizumab (Keytruda) across two clinical trials in head and neck squamous cell carcinoma (HNSCC): a Phase 2 trial in locally advanced HNSCC and a pivotal Phase 2/3 trial in recurrent/metastatic HNSCC. Both trials are recruiting, with the Phase 2/3 trial initiated in January 2025 and the Phase 2 trial initiated in April 2026. With its differentiated dual-mechanism approach and robust clinical program, Bicara targets a large addressable market in HNSCC, where current standard of care leaves significant room for improvement. The company went public via a SPAC merger and carries a valuation of approximately $1.4 billion, reflecting investor optimism around its pipeline potential. Upcoming data readouts from these trials are expected to be key value-driving events, providing initial proof-of-concept and potentially supporting a registration pathway.

Upcoming Catalysts (preview)

• 2027Phase 2/3 Interim Efficacy Data for Ficerafusp alfa + Pembrolizumab in R/M HNSCC40% success
• 2027Phase 2 Topline Results for Ficerafusp alfa + Pembrolizumab in Locally Advanced HNSCC35% success